Sangamo Therapeutics Inc. (NASDAQ: SGMO) stock declined by 1.01% at last close while the SGMO stock price continues to fall in the current-market at last check. There is no recent news available regarding this downfall in SGMO share price, as of now. Sangamo Therapeutics is dedicated to developing genomic therapies that have the ability to change patients’ lives through gene therapy, cell therapy, and genome engineering.
Sangamo Therapeutics, a genomic medicine firm, recently announced that its first quarter financial results for 2021 will be released after the market closes on Tuesday, May 4, 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
On April 28, 2021
SGMO reported its upcoming data demonstrations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which will be held May 11-14, 2021, in an online format.
Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo commented:
SGMO’s zinc finger technology has portrayed its flexibility in a wide variety of clinical fields, and the upcoming presentations at ASGCT will concentrate on one field where there is an especially strong unmet need: neurodegenerative diseases. The capacity for zinc finger protein transcription factors to modify the expression of targeted genes in ALS and Parkinson’s disease is shown in these abstracts. SGMO is inspired by these preliminary findings, which show the accuracy, efficacy, and promise of their transcriptional control technology as a potentially transformative genomic medicine solution for these difficult-to-treat diseases. SGMO is excited to continue their studies.
The presentations involve,
On Tuesday May 11, the presentation will be about “Selective repression of C9ORF72 repeat expansion-containing sense and antisense transcripts for the cure of amyotrophic lateral sclerosis”and “Alpha-synuclein repression by the use of zinc finger protein transcription factors which is a novel therapeutic approach for the cure of Parkinson’s disease”.